← Back to Screener
NuCana plc American Depositary Share (NCNA)
Price$2.29
Favorite Metrics
Price vs S&P 500 (26W)-67.27%
Price vs S&P 500 (4W)29.81%
Market Capitalization$12.67M
All Metrics
Book Value / Share (Quarterly)$0.00
P/TBV (Annual)0.49x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.00
Price vs S&P 500 (YTD)-40.32%
EPS (TTM)$-0.03
10-Day Avg Trading Volume0.05M
EPS Excl Extra (TTM)$-0.03
EPS (Annual)$-0.00
ROI (Annual)-117.40%
Cash / Share (Quarterly)$0.00
ROA (Last FY)-98.39%
EBITD / Share (TTM)$-0.00
ROE (5Y Avg)-154.07%
Cash Flow / Share (Annual)$-0.00
P/B Ratio0.28x
P/B Ratio (Quarterly)0.45x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-1.46x
ROA (TTM)-130.50%
EPS Incl Extra (Annual)$-0.00
Current Ratio (Annual)5.60x
Quick Ratio (Quarterly)5.43x
3-Month Avg Trading Volume0.06M
52-Week Price Return-98.67%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.00
52-Week High$250.00
EPS Excl Extra (Annual)$-0.00
CapEx CAGR (5Y)-34.75%
Tangible BV CAGR (5Y)-25.20%
26-Week Price Return-60.38%
Quick Ratio (Annual)5.45x
13-Week Price Return-31.44%
Total Debt / Equity (Annual)0.03x
Current Ratio (Quarterly)5.60x
Enterprise Value$-22.516
Book Value / Share Growth (5Y)-77.18%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.00
3-Month Return Std Dev87.79%
Net Income / Employee (TTM)$-2
ROE (Last FY)-120.66%
EPS Basic Excl Extra (Annual)$-0.00
Total Debt / Equity (Quarterly)0.03x
EPS Incl Extra (TTM)$-0.03
ROI (TTM)-186.52%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.00
Price vs S&P 500 (52W)-133.30%
Year-to-Date Return-36.39%
5-Day Price Return6.02%
EPS Normalized (Annual)$-0.00
ROA (5Y Avg)-86.72%
Month-to-Date Return63.57%
Cash Flow / Share (TTM)$-1.13
EBITD / Share (Annual)$-0.00
LT Debt / Equity (Annual)1.03x
ROI (5Y Avg)-150.14%
LT Debt / Equity (Quarterly)1.02x
EPS Basic Excl Extra (TTM)$-0.03
P/TBV (Quarterly)0.49x
P/B Ratio (Annual)0.45x
Book Value / Share (Annual)$0.00
Price vs S&P 500 (13W)-33.82%
Beta2.23x
Revenue / Share (TTM)$0.00
ROE (TTM)-189.95%
52-Week Low$1.33
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NCNANuCana plc American Depositary Share | — | — | — | — | $2.29 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
NuCana PLC is a biopharmaceutical company developing cancer treatments based on its proprietary ProTide technology, which delivers higher concentrations of anti-cancer metabolites to tumor cells to overcome drug resistance. The company's pipeline comprises three candidates—NUC-3373, NUC-7738, and Acelarin—with primary operations in the United States.